Related Experiment Videos
Low-dose tiagabine effectiveness in anxiety disorders
James L Schaller1, John Thomas, David Rawlings
1Professional Medical Services of Naples, Naples, Florida, USA.
Medgenmed : Medscape General Medicine
|November 3, 2004
Summary
Tiagabine hydrochloride, a selective GABA reuptake inhibitor (SGRI), effectively treats generalized anxiety disorder. Low initial doses with gradual increases are recommended for anxiety, differing from epilepsy treatment protocols.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Gamma-aminobutyric acid (GABA) is a key inhibitory neurotransmitter in the central nervous system implicated in anxiety disorders.
- Tiagabine hydrochloride functions as a selective GABA reuptake inhibitor (SGRI).
Observation:
- Tiagabine was administered in incremental doses to patients with anxiety, particularly generalized anxiety disorder (GAD).
- Patients included those who had not responded to other anxiety treatments and had a history of substance abuse.
- The study observed tiagabine's effects on anxiety and its tolerability in adult patients.
Findings:
- The SGRI tiagabine demonstrated efficacy in improving anxiety symptoms in patients with GAD.
- Tiagabine was well-tolerated by the majority of patients.
- One case of anxiety secondary to acute antidepressant withdrawal also showed improvement with tiagabine.
Implications:
- Low initial dosing of tiagabine with gradual titration may be sufficient for anxiety treatment.
- Tiagabine presents a potential therapeutic option for generalized anxiety disorder.
- Dosage strategies for anxiety may differ from those used in epilepsy treatment.